Contact
Please use this form to send email to PR contact of this press release:
Oxeia Biopharmaceuticals Oversubscribes First Crowdfunding Campaign, Extends Round for New Investors
TO:
Frank Pietrucha
Oxeia Biopharmaceuticals
+1 202-253-7376